Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Spain / NCT07598903
Starting soon Not applicable

Pharmacy-based Opportunistic Atrial Fibrillation Screening Integrated With Emergency Services (NUMAPLUS-FA)

NCT07598903 · tracked via the Priya Life Science Spain tracker
Sponsor
Centro de Emergencias Sanitarias 061 Andalucía
Phase
Not applicable
Started
2026-06-01
Last updated
2026-05-22

Condition(s) studied

Atrial Fibrillation (Prevention of Stroke)Arrythmia, CardiacMass ScreeningPharmacies

Investigational drug(s) / intervention(s)

Integrated pharmacy-based AF screening circuit

Integrated pharmacy-based AF screening circuit: A coordinated opportunistic screening model integrating community pharmacies, emergency medical services (Salud Responde, CES 061) and primary care physicians. The model comprises: opportunistic patient identification during routine pharmacy visits; 30-second ECG recording using the Kardias 6-lead portable device; real-time data transmission via the Numaplus platform; structured clinical triage by Salud Responde nursing staff; and referral to primary care for definitive diagnosis and treatment. Implementation strategies include a structured EASP-accredited online training programme, ongoing technical support, activity feedback reports and a performance-based financial incentive of 20 euros per complete valid case.

Study summary

This study evaluates the feasibility and fidelity of an opportunistic atrial fibrillation (AF) screening programme conducted in 38 community pharmacies in Seville (Spain), using the Kardias® 6-lead portable ECG device, coordinated with the emergency medical services centre Salud Responde (CES 061) and primary care physicians. Eligible participants are individuals aged 65 years or older without a prior AF diagnosis who attend a participating pharmacy for any routine purpose. The screening consists of a 30-second ECG recording performed by a trained community pharmacist. Positive or indeterminate results are transmitted in real time to Salud Responde for clinical validation and referral to primary care. The study is evaluated using the RE-AIM framework (Reach, Effectiveness, Adoption, Implementation, Maintenance). The primary outcome is protocol fidelity, measured by the Implementation Adherence Grade (IAG). The study is part of the NUMAPLUS project, funded by INTERREG VI-A España-Portugal (POCTEP 2021-2027), co-financed by the European Regional Development Fund (ERDF).

Eligibility

Sex
ALL
Min age
65 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: 1. Age 65 years or older 2. Attending a participating community pharmacy for any routine healthcare purpose 3. No prior documented or patient-reported diagnosis of atrial fibrillation 4. Capacity to provide written informed consent Exclusion Criteria: 1. Confirmed prior diagnosis of atrial fibrillation 2. Implanted pacemaker, implantable cardioverter-defibrillator (ICD) or other intracardiac device 3. Clinically evident haemodynamic instability requiring direct emergency 061 activation (active chest pain, severe dyspnoea, syncope) 4. Concurrent participation in another cardiac rhythm monitoring study 5. Inability to maintain the required position for a 30-second ECG recording

Primary outcome measure(s)

  • Implementation Adherence Grade (IAG) — Through study completion, an average of 6 months
    Implementation Adherence Grade (IAG) Composite fidelity index expressed as the percentage of mandatory protocol items completed per screening case, calculated as (number of mandatory items completed / 5) × 100. The five mandatory items, each scored dichotomously as completed (1) or not completed (0) and weighted equally, are: (1) written informed consent obtained and documented; (2) minimum demographic data recorded; (3) complete CHA₂DS₂-VA score calculated; (4) successful 30-second ECG tracing obtained within a maximum of three attempts; and (5) documented contact with Salud Responde for all cases classified as suspected or indeterminate atrial fibrillation. The pharmacy-level and study-level IAG is the mean of individual case-level IAG values. Target value: ≥90%. Unit of Measure: Percentage of mandatory protocol items completed (single composite index).

Trial sites (1)

FacilityCityRegionStatus
Centro de Emergencias Sanitarias 061 Seville SEVILLA

More Centro de Emergencias Sanitarias 061 Andalucía trials in Spain

Prehospital Emergency Airway Research. Active, not recruiting
Evaluation and Optimization of Telephone Triage Using Artificial Intelligence (AI) Models for the Detection of Demands for Time-dependent Pathology at the Emergency and Urgent Care Coordination Center (CCUE). Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07598903 on ClinicalTrials.gov ↗ ← All trials in Spain